Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 +2.85%94 3-Year EBITDA Growth Rate is 15.40% as of Jun. 2026, which is 28% below its 10-year median of 21.40. GuruFocus rates BSP:RADL3 with a GF Score™ of 94/100 and a GF Value™ of R$27.39 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 525 Healthcare Providers & Services companies, Raia Drogasil ranks better than 58.86% on this metric.
During the past 12 months, Raia Drogasil's average EBITDA Per Share Growth Rate was 19.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 17.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Raia Drogasil was 85.10% per year. The lowest was -5.70% per year. And the median was 21.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Raia Drogasil 3-Year EBITDA Growth Rate Related Terms
For the Pharmaceutical Retailers subindustry, Raia Drogasil's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.40% mean?
Raia Drogasil (BSP:RADL3) has a 3-Year EBITDA Growth Rate of 15.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Raia Drogasil and its competitors. This is 28% below median its historical median of 21.40. According to the industry distribution chart, Raia Drogasil ranks #216 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 41.1%.
Is Raia Drogasil's 3-Year EBITDA Growth Rate too high?
Raia Drogasil's current 3-Year EBITDA Growth Rate of 15.40% is 28% below median its 10-year median of 21.40. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Raia Drogasil's value of 15.40% is 55.6% above this industry median. Based on the distribution chart, Raia Drogasil ranks #216 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's 3-Year EBITDA Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #216 out of 525 companies for 3-Year EBITDA Growth Rate. This puts Raia Drogasil in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Raia Drogasil's value of 15.40% is 55.6% above this benchmark. While the company's 10-year median is 21.40 vs. the industry median of 9.90, Raia Drogasil has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current 3-Year EBITDA Growth Rate of 15.40% is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current 3-Year EBITDA Growth Rate is 15.40%, which is 28% below median its own 10-year median of 21.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$27.39, compared to a current price of R$20.22 — trading 26.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 15.40%, which is 28% below median its 10-year median of 21.40 and 55.6% above the Healthcare Providers & Services industry median of 9.90. Raia Drogasil's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current 3-Year EBITDA Growth Rate is 15.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$20.22 is trading 26.2% below its estimated GF Value™ of R$27.39.
GuruFocus considers Raia Drogasil to be Modestly Undervalued.
Key valuation signals for BSP:RADL3:
3-Year EBITDA Growth Rate: 15.40% (28% below median its 10-year median of 21.40)
GF Value™: R$27.39 vs. price of R$20.22 (26.2% below fair value)
Industry Position: 55.6% above the Healthcare Providers & Services median (#216 of 525)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
94GF Score
Get the complete analysis for BSP:RADL3
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
